Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06810635

Polyphenol Metabotypes in People With Diabetes Type 2

Status
Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
University Hospital, Ghent · Academic / Other
Sex
All
Age
40 Years – 85 Years
Healthy volunteers
Accepted

Summary

This cross-sectional study seeks to characterize the overall polyphenol metabotype in patients with T2DM in comparison to age-matched individuals without diabetes. Additionally, the study aims to identify factors that influence the polyphenol metabotype (transit time and gut microbial capacity to degrade polyphenols in particular).

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTOral Polyphenol Challenge Test / PPPILPatients will receive a so-called oral polyphenol challenge test. It is a pill containing a multitude of polyphenol classes (doi: 10.1093/cdn/nzac072.020)
DIAGNOSTIC_TESTfasting blood sampleFasting blood sample will be obtained for determination of markers of metabolic health.
DIAGNOSTIC_TESTFasting urine collectionSubjects collect morning urine (or the urine thereafter ) in a separate urine container and write down the time of urine collection for determination of polyphenol metabolites
DIAGNOSTIC_TEST24 hours urine collectionSubjects collect urine over the entire 24h. for determination of polyphenol metabolites
OTHERQuestionnairesQuestionnaires will be performed to collect information on lifestyle and baseline characteristics: physical activity (IPAQ), sleep (PSQI), drinking and smoking behaviour, drug intake and medical record.
DIAGNOSTIC_TESTStool collectionOptional: some subjects collect stool samples to test the capacity of the microbiome to degrade polyphenols with a batch experiment.
DIAGNOSTIC_TESTTransit time determinationSubjects take a pill containing 90mg of royal blue dye (E133) together with the polyphenol pill to determine their transit time. When their stool discolours, the subjects notify the researcher.

Timeline

Start date
2026-03-04
Primary completion
2028-11-01
Completion
2028-12-01
First posted
2025-02-05
Last updated
2026-03-23

Locations

2 sites across 1 country: Belgium

Source: ClinicalTrials.gov record NCT06810635. Inclusion in this directory is not an endorsement.